Bcal Diagnostics Limited · ASX:BDX
Bcal Diagnostics — JMM & Ethica Capital - Innovation & Investment Insights (May 2024)
16 slides from Bcal Diagnostics's conference presentation, May 2, 2024
Slide 1: Driving a New Paradigm in Breast Cancer Diagnostics
BCAL DIAGNOSTICS LIMITED ASX: BDX 2 MAY 2024 JMM & ETHICA CAPITAL- Innovation & Investment Insights DRIVING A NEW PARADIGM IN BREAST CANCER DIAGNOSTICS Jayne Shaw CORPORATE PRESENTATION
Slide 2: Important Notice and Disclaimer
IMPORTANT NOTICE AND DISCLAIMER This presentation (Presentation) has been prepared by BCAL Diagnostics The forward-looking statements are based on information available to BCAL Not An Offer Ltd ABN 51 142 051 223 (BCAL or the Company). as at the date of this Presentation. Circumstances may change an
Slide 3: Corporate Presentation - Dr David Speakman
BCA Laiasnostcs ~ DR DAVID SPEAKMAN SURGICAL ONCOLOGIST
Slide 4: Company Metrics
COMPANY METRICS ASX Code BDX Share Price 12 April 2024 $0.10 Shares on Issue 252M Unlisted Options 4.5M Cash 31 March 2024 $3.3M Top 20 Shareholders 57% CORPORATE PRESENTATION 4
Slide 5: Company Overview
COMPANY OVERVIEW ▪ Founded in 2010, BCAL Diagnostics is focused on transforming early detection and screening for breast cancer for women worldwide with the introduction of its innovative blood test BREASTEST® BREASTEST® ▪ Over 5,000 prospective blood samples have been collected by BCAL to drive tes
Slide 6: Commercial Pathway
COMMERCIAL PATHWAY A 3-year roadmap to saving lives underpinned by a reproducible 01 Australian Launch ▪ Launch of BREASTEST® in Australia late 2024 & first revenues lipidomic platform and a proprietary biobank of growing data. ▪ Initial focus on NSW & Victoria where we already have a strong footpri
Slide 7: A Global Commercial Opportunity
A GLOBAL COMMERCIAL OPPORTUNITY Breast cancer is the world’s most prevalent cancer in women { WCRFI 2.1 Million Mammograms $2.3B On average 13% of 2023 to 57 People in 2021 in AUS BSA women in the US are or will be diagnosed with will develop an invasive form of $6.9B breast cancer everyday breast c
Slide 8: Breast Screening – Mammogram Current Standard of Care
Breast Screening – Mammogram Current Standard of Care 28% 40+ New data from the 2.1M 42% USA points to a 42% (>20,000) of all new Guidelines limit Mammograms of eligible women cancer cases in AU access to routine occurred in in Australia do not reduction women will be breast screening to those in mo
Slide 9: BREASTEST Will Be Used as a Screening Tool
BREASTEST® WILL BE USED AS A SCREENING TOOL SCREENING DIAGNOSTICS Contrast enhanced BREASTEST® Mammography Ultrasound 3D Mammography MRI mammography ▪ Simple blood test ▪ Painful procedure ▪ Used for mass/lesion ▪ Painful procedure ▪ Painful procedure ▪ High sensitivity differentiation, no ▪ Solves
Slide 10: A Lipid Blood Test with Automated Analysis
A LIPID BLOOD TEST WITH AUTOMATED ANALYSIS ~$300 Proposed cost of test to the patient, following independent research and } ALEARNING LIPIDOMIC PLATFORM THAT INCORPORATES AI MACHINE AND LEVERAGES ROBUST SCIENTIFIC RESEARCH focus group BREASTEST® AT COLLECTION CENTRE TRANSIT AT TESTING LABORATORY Log
Slide 11: Commercial Launch on Track for Late 2024
COMMERCIAL LAUNCH ON TRACK FOR LATE 2024 } Commercial strategy to advance relationships with existing partners to launch BREASTEST® in specialised clinics with first revenues expected to be delivered immediately following launch. AP MA JU JU AU SE O NOV DEC J R Y N L G P C ’24 ‘24 A ’24 ’24 ’24 ’24
Slide 12: BCAL Is Working with Clinicians from Leading Centres Around the Globe
BCAL IS WORKING WITH CLINICIANS FROM LEADING CENTRES AROUND THE GLOBE ▪ Lakeview Private Hospital ▪ Royal North Shore Hospital ▪ Dudley Private Hospital ▪ BreastScreen RPAH ▪ Westmead Breast Cancer Institute A pilot study assessing the feasibility of using the BCAL test for early diagnosis of breast
Slide 13: Clinic Advisory Board
CLINIC ADVISORY BOARD } Eminent and influential Breast Clinicians form a National Key Opinion Leader & Clinical Excellence Forum to enhance trust, provide advice and inform the BCAL program Dr David Speakman Prof Bruce Mann Dr Corinne Ooi A/Prof. James French Prof. Elisabeth Elder A/Prof. Cindy Mak
Slide 14: BREASTEST Has Strong and Growing Intellectual Property
BREASTEST HAS STRONG AND TM GROWING INTELECTUAL PROPERTY Expected Title IP covered Jurisdiction Status Patent number Priority date expiry date Methods for detecting cancer* Use of plasma lipids as a diagnostic method to detect breast and lung cancer AU (AU1) Granted AU Pat. No. 2011270968 23 June 20
Slide 15: Board and Executives
BOARD AND EXECUTIVES Jayne Shaw Hon Ron Phillips AO Mark Burrows AO Jonathan Trollip Dr. John Hurrell PhD Dr David Darling Executive Chair Non-executive Director Independent Independent Independent Non-Executive Director Successful businesswoman, Health policy expert, previously Non-executive direct
Slide 16: Thank you
Thank you Breast cancer blood screening. For every woman, everywhere. Jayne Shaw Shane Ryan Executive Chair Chief Executive Officer jshaw@bcaldiagnostics.com sryan@bcaldiagnostics.com BCAL Diagnostics Limited www.bcaldiagnostics.com ABN 51 142 051 223 Suite 506, Lvl 5, 50 Clarence Street Sydney NSW
BCAL Diagnostics — JMM & Ethica Capital - Innovation & Investment Insights (May 2024) on 6ix